Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Renovorx Inc (NQ: RNXT )

1.400 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EDT, May 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.400
Bid (Size) 1.000 (1)
Ask (Size) 1.670 (9)
Prev. Close 1.400
Today's Range 1.400 - 1.400
52wk Range 0.5306 - 3.290
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
RenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024
From RenovoRx, Inc.
Via Business Wire
RNXT Stock Earnings: RenovoRx Beats EPS for Q1 2024
RNXT stock results show that RenovoRx beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
-29.29%
-29.29%
1 Month
+13.82%
+13.82%
3 Month
+1.45%
+1.45%
6 Month
+129.89%
+129.89%
1 Year
-31.03%
-31.03%

More News

Read More
RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024
From RenovoRx, Inc.
Via Business Wire
RenovoRx Regains Compliance with Nasdaq Stockholders’ Equity Requirement
From RenovoRx , Inc.
Via Business Wire
RNXT Stock Earnings: RenovoRx Meets EPS for Q4 2023
Via InvestorPlace
RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
From RenovoRx, Inc.
Via Business Wire
RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026
From RenovoRx, Inc.
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
RenovoRx Announces $11.1 Million at Market Private Placement
From RenovoRx, Inc.
Via Business Wire
RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024
From RenovoRx, Inc.
Via Business Wire
RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024
From RenovoRx, Inc.
Via Business Wire
RenovoRx Highlights Key Leadership Promotions
From RenovoRx, Inc.
Via Business Wire
RenovoRx CEO Issues Letter to Shareholders
From RenovoRx, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
RenovoRx Closes $6.1 Million Private Placement
From RenovoRx, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why DouYu International Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Clinical Trials at Major University; New Application Targeting Tumors with an IP Portfolio of 9 Patents Issued, 9 Pending for Cancer Treatments Partnered with Imugene: RenovoRx (NASDAQ: RNXT)
Via Get News
Topics Intellectual Property
Exposures Intellectual Property
RenovoRx (NASDAQ: RNXT) Elevates IP Portfolio with New Application and Advances Cancer Treatments in Phase 3 Clinical Trials
Via Get News
Topics Intellectual Property
Exposures Intellectual Property
RenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct Cancer
From RenovoRx, Inc.
Via Business Wire
RenovoRx Announces Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
From RenovoRx, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.